BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress
BrainStorm is conducting a Phase 2 open-label, US-based, multicenter study of repeated intrathecal administration of NurOwn® in participants with Progressive Multiple Sclerosis. The Phase 2 study will evaluate validated MS efficacy outcome measures as well as innovative and validated CSF and serum biomarkers. The efficacy outcome data presented at this ECTRIMS meeting provides a natural history cohort matched to the phase 2 patient population. The phase 2 MS study is actively enrolling participants and should be fully enrolled by early 2020.
Meeting and Presentation Details:
|ECTRIMS Late Breaking News ePoster:
|Title: Disability improvement assessed by multiple sclerosis functional composite in progressive MS patients from the CLIMB Study|
|Authors: T. Chitnis, M. Rosso, H. Yano, B. Glanz, M.C. Manieri, R. Kern, S. Ward, M. Mehra, H. Weiner, B. Healy, Brigham and Women's Hospital, Ann Romney Center for Neurologic Diseases and Massachusetts General Hospital, Boston, MA, BrainStorm Cell Therapeutics, NY, NY.|
|Session: Poster Session 3|
|Date: Friday, 13 September 2019|
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn® treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Source: BrainStorm Cell Therapeutics Inc.